Celltrion said on the 13th that Remsima, Yuflyma and Vegzelma ranked No. 1 in prescriptions in Europe. Remsima and Yuflyma are biosimilars that treat autoimmune diseases, and Vegzelma is a biosimilar that treats metastatic colorectal cancer and breast cancer.
According to the pharmaceutical market research firm IQVIA, the Remsima product family recorded a 69% market share in Europe in the second quarter of this year. Yuflyma and Vegzelma had market shares of 26% and 24%, respectively. In addition, Herzuma and Truxima are also being prescribed in Europe. Herzuma treats stomach cancer and breast cancer, and Truxima treats blood cancer.
The company is expanding the countries where it sells Omiclob, a chronic idiopathic urticaria treatment introduced in September. Additional products, including Eydenzelt, an ophthalmic disease treatment, are slated for launch within the year. A Celltrion official said, "We will strengthen our direct sales capabilities in Europe."